<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00724529</url>
  </required_header>
  <id_info>
    <org_study_id>CR100771</org_study_id>
    <secondary_id>REMICADECRD4015</secondary_id>
    <nct_id>NCT00724529</nct_id>
  </id_info>
  <brief_title>Post Marketing Surveillance of Remicade</brief_title>
  <official_title>Post Marketing Surveillance of Remicade in Inflammatory Bowel Disease (IBD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Korea, Ltd., Korea</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Korea, Ltd., Korea</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand the safety and effectiveness of infliximab when
      used in clinical practice. This is a post-marketing surveillance study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigator will record continuously from the first patient since the day of contract to
      the numbers of patients of contract based on Remicade approval.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety of Remicade Injection (Infliximab) when used in clinical practice</measure>
    <time_frame>The maximum period for observation in this surveillance would be 30 weeks (6 administrations) for patients with Crohn's disease and 24~30 weeks (6 administrations) for patients with Ankylosing spondylitis.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of Remicade Injection (Infliximab) when used in clinical practice</measure>
    <time_frame>The maximum period for observation in this surveillance would be 30 weeks (6 administrations) for patients with Crohn's disease and 24~30 weeks (6 administrations) for patients with Ankylosing spondylitis.</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">938</enrollment>
  <condition>Crohn's Disease</condition>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>Serious Active Crohns Disease</arm_group_label>
    <description>Patients with severe active Crohns Disease who do not show any response to treatment with corticosteroids or immunosuppressive agents, and have no drug tolerance or contraindications to such treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fistula-Type Active Crohns Disease</arm_group_label>
    <description>Patients with fistula-type Crohns Disease who do not show any response to general treatments such as antibiotics, drainage, or immunosuppressant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ankylosing Spondylitis</arm_group_label>
    <description>Patients with Ankylosing Spondylitis who do not show adequate response to general treatments and with increased serological indices related to severe axial symptoms and inflammation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>Infliximab 5 mg/kg IV given in a schedule according to the official label, based on the indication it is being used for.</description>
    <arm_group_label>Serious Active Crohns Disease</arm_group_label>
    <arm_group_label>Fistula-Type Active Crohns Disease</arm_group_label>
    <arm_group_label>Ankylosing Spondylitis</arm_group_label>
    <other_name>SCH 215596</other_name>
    <other_name>Remicade</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The population of subjects will mainly be taken from the digestive or rheumatoid
        departments of internal medicine in university or general hospitals, where patients with
        Crohn's Disease and Ankylosing Spondylitis are generally treated. The period of
        surveillance is from 23 AUG 2005 to 22 AUG 2011.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe active Crohn's disease: the patients with severe active Crohn's disease who do
             not show any response to the treatment with corticosteroid or immunosuppressive
             agents, have no drug tolerance, or are contraindicated to such treatments.

          -  Fistula-type active Crohn's disease: the patients with fistula-type active Crohn's
             disease who do not show any response to general treatments such as antibiotics,
             drainage, or immunosuppressant.

          -  Ankylosing spondylitis: the patients with ankylosing spondylitis who do not show
             adequate response to general treatments, and with increased serological indices
             related to severe axial symptoms and inflammation.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Korea, Ltd., Korea Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Korea, Ltd., Korea</affiliation>
  </overall_official>
  <removed_countries>
    <country>Korea, Republic of</country>
  </removed_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2008</study_first_submitted>
  <study_first_submitted_qc>July 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2008</study_first_posted>
  <last_update_submitted>January 21, 2013</last_update_submitted>
  <last_update_submitted_qc>January 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's Disease</keyword>
  <keyword>Ankylosing Spondylitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

